What is the average increase in blood glucose levels with Repatha (Evolocumab) in a typical adult patient with hypercholesterolemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Blood Glucose Effects of Repatha (Evolocumab)

Repatha (evolocumab) does not increase blood glucose levels and has no clinically meaningful effect on glycemic control in patients with or without diabetes. 1, 2

Evidence from Major Clinical Trials

The most robust evidence comes from the FOURIER trial, which specifically analyzed glycemic effects in 27,564 patients over a median follow-up of 2.2 years. 1

Key Findings on Glucose Metabolism

  • HbA1c levels remained similar between evolocumab and placebo groups throughout the study period in patients with diabetes, prediabetes, and normoglycemia 1
  • Fasting plasma glucose (FPG) showed no differences between treatment groups over time across all glycemic categories 1
  • No increased risk of new-onset diabetes was observed (HR 1.05,95% CI 0.94-1.17) in patients without diabetes at baseline 1
  • In patients with prediabetes specifically, evolocumab showed no increased diabetes risk (HR 1.00,95% CI 0.89-1.13) 1

Additional Supporting Evidence

The BERSON trial (981 patients with type 2 diabetes) demonstrated that evolocumab combined with atorvastatin showed no clinically meaningful differences in changes over time in glycemic variables (fasting serum glucose and HbA1c) between evolocumab and placebo groups. 2

Clinical Implications

Evolocumab is safe for use in patients with diabetes or at risk for diabetes without concern for worsening glycemic control. 1, 2 This contrasts sharply with some other lipid-lowering agents:

  • Niacin significantly increases blood glucose, particularly at high doses, though modest doses (750-2,000 mg/day) cause only modest changes generally amenable to adjustment of diabetes therapy 3
  • Statins are associated with modestly increased risk of incident diabetes 3

Common Pitfalls to Avoid

  • Do not withhold evolocumab from diabetic patients due to glucose concerns—the evidence clearly shows no adverse glycemic effects 1, 2
  • Do not require more frequent glucose monitoring specifically because of evolocumab initiation, as it does not affect glucose metabolism 1
  • Evolocumab's cardiovascular benefits are consistent in patients with and without diabetes (HR 0.83 for primary endpoint in diabetics vs 0.87 in non-diabetics, p-interaction=0.60) 1

References

3
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is the best course of action for a middle-aged male with diabetes mellitus, hyperlipidemia, hypertension, fatty liver, and hypogonadism, who is experiencing adverse effects from Ozempic (semaglutide) 1 mg SQ once a week, and has elevated total cholesterol and LDL levels, while also facing issues with insurance coverage for Repatha (evolocumab)?
Can pambezoic acid be combined with evolocumab (Repatha)?
Can Repatha (evolocumab) cause hypertriglyceridemia?
What is the recommended duration of treatment with evolocumab (PCSK9 inhibitor)?
Can Mounjaro (tirzepatide) and Repatha (evolocumab) be administered on the same day in a patient with type 2 diabetes and high cholesterol, or should they be spaced out to minimize potential interactions?
What is the initial step in evaluating a woman with an intrauterine device (IUD) and suspected premature ovarian insufficiency (POI)?
What is the best treatment approach for a middle-aged or older adult patient with a history of calcification tendinitis in the right shoulder, now presenting with osteoarthritis, significant pain, and impaired functional ability, including difficulty sleeping and extending the right arm over the head?
What are the management steps for a patient with hyponatremia after pituitary surgery, with a history of pituitary tumor and currently taking losartan (angiotensin II receptor antagonist)?
If a patient failed Lexapro (escitalopram) due to weight gain, would Zoloft (sertraline) be a suitable alternative?
What is the appropriate evaluation and management of unintentional weight loss in an adult over 65 years of age with potential underlying chronic medical conditions, such as cancer, diabetes, or dementia?
What are the diagnostic steps and treatment options for a patient with suspected pulmonary hypertension?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question